News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website


Pfizer to withdraw Bextra from US, EU and Canadian markets

Posted on: 04/08/2005

Pfizer to withdraw Bextra from US, EU and Canadian markets

The FDA has asked Pfizer to withdraw its COX-2 drug, Bextra, from the US market "because its overall risk versus benefit profile is unfavourable." The agency also requested that labels for Celebrex, and all other prescription NSAIDS, carry a boxed warning highlighting the potential for cardiovascular and gastrointestinal risks. Additionally, Pfizer will suspend sales of Bextra in the EU and Canada, at the request of their respective regulators.

Source: First Word [4/8/05]

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557